China's biopharmaceutical industry has entered its "second half," centered on "commercialization efficiency," making downstream purification processes a key competitive factor. Traditional batch processes are inefficient and costly. Under pressure from healthcare cost control and overseas competition, the industry urgently needs to reduce costs and increase efficiency through "continuous biological processing" and "process intensification." To overcome the bottleneck of relying on imported core
Downstream purification makes up over 60% of biologic production costs, a major bottleneck for affordability and profits. Driven by high chromatography costs and supply chain risks, the industry is pursuing technology-led cost reduction via process innovation, CDMO outsourcing, and diversified supply chains. This paper reviews the cost structure and solutions for efficient, stable manufacturing.
This paper reviews three key trends: continuous manufacturing, AI & digital twins, and green materials & circular economy. Their integration is building smarter, more efficient biopharmaceutical factories, delivering more accessible and reliable medicines to patients.
